Piramal Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Piramal Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 25% in 3 years, but profit fell: ₹8 less profit per ₹100 of extra sales. Lower than 90% of Healthcare companies in India.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 17% of its market value (net debt). Lower than 88% of Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹49 is tangible; the rest is goodwill and other intangibles, often from buying other companies. Less tangible than 87% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.6×Over the last 3 years its own operating cash covered its investment spending (capex) 1.6 times.
Higher than 59% of Healthcare companies in India.
Cash Locked Ratio
₹29For every ₹100 of sales, ₹29 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹32 tied up three years earlier.
More money tied up than 59% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
−₹8Sales grew 25% in 3 years, but profit fell: ₹8 less profit per ₹100 of extra sales.
Lower than 90% of Healthcare companies in India.
Asset Productivity Ratio
+25% / +24%In 3 years sales changed by +25% while total assets changed by +24%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
1.4×Debt due within a year is covered 1.4 times by its yearly operating cash.
Higher than 52% of Healthcare companies in India.
Cash Cushion Ratio
−17%Debt, after subtracting cash, equals 17% of its market value (net debt).
Lower than 88% of Healthcare companies in India.
Tangible Assets Ratio
77%Of every ₹100 the company owns, ₹77 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 86% of Healthcare companies in India.
Tangible Net Worth Ratio
49%Of every ₹100 of net worth, ₹49 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 87% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Piramal Pharma Limited made a loss over the last year. Piramal Pharma Limited owes ₹0.55 for every ₹1 it owns. Piramal Pharma Limited made a loss in the year to Mar 2026, after a profit the year before.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
LossPiramal Pharma Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.17The share price is 3.17 times Piramal Pharma Limited's book value per share, lower than 68% of Healthcare companies in India.
Market cap
₹25,837 CrThe total market value of all of Piramal Pharma Limited's shares at today's price (share price × number of shares), larger than 80% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹8,163 CrWhat Piramal Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹61.60Net worth divided by the number of shares. The share price of ₹194.99 is 3.2 times this, which is the P/B above.
Return on equity (ROE)
-3.9%Piramal Pharma Limited lost 3.9% of its shareholders' money over the last year, lower than 96% of Healthcare companies in India.
Owes vs Owns
0.55×Piramal Pharma Limited owes ₹0.55 for every ₹1 it owns (moderate), higher than 89% of Healthcare companies in India.
Dividend yield
NonePiramal Pharma Limited does not currently pay a dividend.
Revenue growth
-3%Revenue fell 3% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Profit growth
LossPiramal Pharma Limited made a loss in the year to Mar 2026, after a profit the year before.
Profit margin
-3.7%Piramal Pharma Limited lost ₹4 for every ₹100 of revenue.
Interest cover
0.5×Piramal Pharma Limited's operating profit covered its interest costs 0.5 times in the year to Mar 2026.
Cash vs debt
Net debtPiramal Pharma Limited had ₹4,340 Cr more debt than cash (net debt) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Piramal Pharma Limited: ₹25,837 Cr ÷ ₹8,163 Cr (31 Mar 2026) = 3.2.
What is Piramal Pharma Limited's return on equity?
Piramal Pharma Limited lost 3.9% of its shareholders' money over the last year, lower than 96% of Healthcare companies in India.
How much does Piramal Pharma Limited owe compared with what it owns?
Piramal Pharma Limited owes ₹0.55 for every ₹1 it owns (moderate), higher than 89% of Healthcare companies in India.
Does Piramal Pharma Limited pay a dividend?
No. Piramal Pharma Limited does not currently pay a dividend.
Is Piramal Pharma Limited's revenue growing?
Revenue fell 3% in the year to Mar 2026, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.